4-(5-cyclobutyl-3-methyl-1H-pyrazol-4-yloxy)-2,6-dimethyl-benzonitrile | 1020732-24-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(5-cyclobutyl-3-methyl-1H-pyrazol-4-yloxy)-2,6-dimethyl-benzonitrile
• 英文别名: 4-[(3-cyclobutyl-5-methyl-1H-pyrazol-4-yl)oxy]-2,6-dimethylbenzonitrile
• CAS: 1020732-24-4
• 化学式: C₁₇H₁₉N₃O
• 分子量: 281.357
• InChiKey: GZGFQYBESGPZSP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  61.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compounds Useful In Therapy
  申请人：Gibson Karl Richard

  公开号：US20080096950A1

  公开（公告）日：2008-04-24

  Compounds of Formula (I): and pharmaceutically acceptable salts, solvates (including hydrates) of said compounds and salts, or prodrugs of said compound, or pharmaceutically acceptable salts or solvates of said prodrugs, wherein the substituents are as herein defined, are useful in therapy, for example they may be useful for treating progesterone-mediated conditions such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.

  化合物的化学式（I）： 以及所述化合物及其盐、溶剂化合物（包括水合物）和盐、或所述化合物的前药，或所述前药的药学上可接受的盐或溶剂化合物，其中取代基如本文所定义，可用于治疗，例如它们可能对治疗孕激素介导的疾病如子宫内膜异位症、子宫肌瘤（平滑肌瘤）、月经过多、子宫腺肌病、原发性和继发性痛经（包括性交疼痛、排便疼痛和慢性盆腔疼痛症状）或慢性盆腔疼痛综合症等方面具有用处。
• [EN] PYRAZOLYL-4-OXY-BENZONITRILE DERIVATIVES USEFUL IN TREATING ENDOMETRIOSIS<br/>[FR] Dérivés de pyrazolyl-4-oxy-benzonitrile utiles pour le traitement de l'endométriose
  申请人：PFIZER LTD

  公开号：WO2008047224A1

  公开（公告）日：2008-04-24

  [EN] Compounds of Formula (I): and pharmaceutically acceptable salts, solvates (including hydrates) of said compounds and salts, or prodrugs of said compound, or pharmaceutically acceptable salts or solvates of said prodrugs, wherein the substituents are as herein defined, may be useful in therapy, for example they may be useful for treating progesterone-mediated conditions such as endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
  [FR] L'invention concerne des composés de formule (I) : (I) et les sels pharmaceutiquement acceptables, les solvates (y compris les hydrates) desdits composés et sels, ou les promédicaments desdits composés ou les sels pharmaceutiquement acceptables ou solvates desdits promédicaments, les substituants étant tels que définis dans le présent document, lesdits composés étant utiles en thérapie, par exemple pour le traitement de maladies induites par la progestérone telles que l'endométriose, le fibrome utérin (léiomyome), la ménorragie, l'adénomyose, la dysménorrhée primaire et secondaire (y compris les symptômes de la dyspareunie, de la dyschexie et de la douleur pelvique chronique) ou le syndrome de la douleur pelvique chronique.